Osiris Therapeutics [OSIR] won a potential $224.7 million contract from the Defense Department for the development and possible purchase of Prochymal, an adult stem cell therapy, for the repair of gastrointestinal injury resulting from radiation exposure. Initially Osiris will receive $4.2 million this year to continue development of Prochymal for acute radiation syndrome (ARS). Once the Food and Drug Administration (FDA) approves the drug for ARS, the contract provides for the purchase of up to 20,000 doses, at $10,000 per…
Osiris Nabs $225M DoD Contract for Acute Radiation Syndrome
SHARE:
